Kuros Biosciences Ltd. KURN

Ad-hoc announcement pursuant to Article 53 of the SIX listing rulesKuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability Schlieren (Zurich), Switzerland, August 13, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial and operational results for the first half of 2026.Financial HighlightsTotal Medical Device sales increased 45% to USD 92.4 million in H1 2026 (H1 20

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich Schlieren (Zürich), Switzerland, June 17, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, is pleased to announce today’s Capital Markets Day on Wednesday, June 17, 2026, at 9am CEST, at the Mandarin Oriental Savoy, Zürich, Switzerland. The event will also be available virtually via live webcast. Capital Markets Day wil

As European markets navigate a period of uncertainty, marked by mixed economic signals and geopolitical tensions, investors are keenly observing growth companies that demonstrate resilience. In such an environment, stocks with high insider ownership can be particularly appealing as they often signal confidence from those closest to the company's operations and future prospects.

As European markets navigate a period of uncertainty marked by geopolitical tensions and economic contractions, investors are increasingly focusing on companies that demonstrate resilience and potential for growth. In this environment, stocks with strong insider ownership can be particularly appealing as they often indicate confidence from those closest to the company's operations.

As European markets navigate a period of uncertainty, marked by mixed economic signals and geopolitical developments, investors are increasingly focusing on companies with strong growth potential and high insider ownership. In such an environment, stocks that combine robust growth prospects with significant insider stakes can offer a compelling proposition, as they may align management interests with those of shareholders while potentially capitalizing on market opportunities.

As European markets navigate a period of uncertainty marked by mixed economic signals and geopolitical tensions, investors are increasingly focused on identifying resilient growth opportunities. In this context, companies with strong insider ownership often attract attention for their potential alignment of management and shareholder interests, which can be particularly appealing during volatile market conditions.

The European market has shown resilience with the pan-European STOXX Europe 600 Index edging up slightly, as investors remain hopeful for geopolitical resolutions that could stabilize energy markets and boost economic confidence. In this environment, identifying high-growth tech stocks involves looking for companies with strong innovation capabilities and adaptability to current trends such as artificial intelligence and digital transformation, which can offer promising potential despite...

As European markets navigate the complexities of geopolitical developments and economic adjustments, indices like Germany's DAX and France's CAC 40 have shown resilience with notable gains. In this environment, growth companies with high insider ownership can offer unique insights into potential stability and long-term value, as insiders' vested interests may align closely with shareholder success.

As European markets navigate the complexities of geopolitical developments and economic shifts, such as the ongoing U.S.-Iran negotiations and supply chain challenges, investors are increasingly focused on identifying growth opportunities within the region. In this environment, companies with high insider ownership can offer potential advantages, as they often align management's interests with those of shareholders, fostering long-term growth strategies amidst market uncertainties.

Wondering whether Kuros Biosciences at CHF 19.85 is still offering value or if most of the opportunity has already been priced in? This article walks through the key checks investors often use to frame that question. The stock has pulled back recently, with the share price down 0.8% over the last week, 18.8% over the past month, 25.6% year to date and 17.1% over the last year, after a very large gain over three years that is more than 10x and an 873.0% gain over five years. Recent coverage...

Annual General Meeting of Kuros Biosciences approves all resolutions Schlieren (Zurich), Switzerland, April 15, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the year 2025 and took note of the Reports of the Auditors. Shareholders also ratified the Compensation Repor

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total product sales rose by 51% to USD 43.4 million (Q1 2025: USD 28.8 million)Direct MagnetOs™ product sales increased by 51% to USD 42.9 million (Q1 2025: USD 28.4 million)Group EBITDA reached USD 2.9 million (Q1 2025: EBITDA of USD 2.0 million)Group adjusted EBITDA* amounted to USD 5.7 million, equaling a marg

As European markets navigate a landscape of interest rate assessments and trade uncertainties, the pan-European STOXX Europe 600 Index remains relatively stable, with major indexes like Italy's FTSE MIB and Germany's DAX showing modest gains. In this environment, identifying stocks that are potentially undervalued can offer intriguing opportunities for investors seeking to capitalize on discrepancies between market prices and intrinsic value estimates.